Table of Contents

1 Study Coverage

• 1.1 Vyxeos Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Vyxeos Market Size Growth Rate by Product
  • 1.4.2 Daunorubicin 29 mg/m2 and Cytarabine 65 mg/m2
  • 1.4.3 Daunorubicin 44 mg/m2 and Cytarabine 100 mg/m2
• 1.5 Market by End User
  • 1.5.1 Global Vyxeos Market Size Growth Rate by End User
  • 1.5.2 Hospital
  • 1.5.3 Pharmacy
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Vyxeos Market Size
  • 2.1.1 Global Vyxeos Revenue 2014-2025
  • 2.1.2 Global Vyxeos Sales 2014-2025
• 2.2 Vyxeos Growth Rate by Regions
  • 2.2.1 Global Vyxeos Sales by Regions
  • 2.2.2 Global Vyxeos Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Vyxeos Sales by Manufacturers
  • 3.1.1 Vyxeos Sales by Manufacturers
  • 3.1.2 Vyxeos Sales Market Share by Manufacturers
  • 3.1.3 Global Vyxeos Market Concentration Ratio (CR5 and HHI)
• 3.2 Vyxeos Revenue by Manufacturers
  • 3.2.1 Vyxeos Revenue by Manufacturers (2014-2019)
  • 3.2.2 Vyxeos Revenue Share by Manufacturers (2014-2019)
• 3.3 Vyxeos Price by Manufacturers
• 3.4 Vyxeos Manufacturing Base Distribution, Product Types
  • 3.4.1 Vyxeos Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Vyxeos Product Type
  • 3.4.3 Date of International Manufacturers Enter into Vyxeos Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Vyxeos Sales by Product
• 4.2 Global Vyxeos Revenue by Product
• 4.3 Vyxeos Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Vyxeos Breakdown Data by End User

6 North America

• 6.1 North America Vyxeos by Countries
  • 6.1.1 North America Vyxeos Sales by Countries
  • 6.1.2 North America Vyxeos Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Vyxeos by Product
• 6.3 North America Vyxeos by End User

7 Europe

• 7.1 Europe Vyxeos by Countries
  • 7.1.1 Europe Vyxeos Sales by Countries
  • 7.1.2 Europe Vyxeos Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Vyxeos by Product
• 7.3 Europe Vyxeos by End User

8 Asia Pacific

• 8.1 Asia Pacific Vyxeos by Countries
  • 8.1.1 Asia Pacific Vyxeos Sales by Countries
  • 8.1.2 Asia Pacific Vyxeos Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Vyxeos by Product
• 8.3 Asia Pacific Vyxeos by End User

9 Central & South America

• 9.1 Central & South America Vyxeos by Countries
  • 9.1.1 Central & South America Vyxeos Sales by Countries
  • 9.1.2 Central & South America Vyxeos Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Vyxeos by Product
• 9.3 Central & South America Vyxeos by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Vyxeos by Countries
  • 10.1.1 Middle East and Africa Vyxeos Sales by Countries
  • 10.1.2 Middle East and Africa Vyxeos Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Vyxeos by Product
• 10.3 Middle East and Africa Vyxeos by End User

11 Company Profiles

• 11.1 Celator Pharmaceuticals
  • 11.1.1 Celator Pharmaceuticals Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Celator Pharmaceuticals Vyxeos Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Celator Pharmaceuticals Vyxeos Products Offered
  • 11.1.5 Celator Pharmaceuticals Recent Development
• 11.2 Jazz Pharma
  • 11.2.1 Jazz Pharma Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Jazz Pharma Vyxeos Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Jazz Pharma Vyxeos Products Offered
  • 11.2.5 Jazz Pharma Recent Development

12 Future Forecast

• 12.1 Vyxeos Market Forecast by Regions
  • 12.1.1 Global Vyxeos Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Vyxeos Revenue Forecast by Regions 2019-2025
• 12.2 Vyxeos Market Forecast by Product
  • 12.2.1 Global Vyxeos Sales Forecast by Product 2019-2025
  • 12.2.2 Global Vyxeos Revenue Forecast by Product 2019-2025
• 12.3 Vyxeos Market Forecast by End User
• 12.4 North America Vyxeos Forecast
• 12.5 Europe Vyxeos Forecast
• 12.6 Asia Pacific Vyxeos Forecast
• 12.7 Central & South America Vyxeos Forecast
• 12.8 Middle East and Africa Vyxeos Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Vyxeos Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

VYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine,
The global Vyxeos market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Vyxeos market based on company, product type, end user and key regions.

This report studies the global market size of Vyxeos in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Vyxeos in these regions.
This research report categorizes the global Vyxeos market by top players/brands, region, type and end user. This report also studies the global Vyxeos market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Celator Pharmaceuticals
Jazz Pharma

Market size by Product
Daunorubicin 29 mg/m2 and Cytarabine 65 mg/m2
Daunorubicin 44 mg/m2 and Cytarabine 100 mg/m2
Market size by End User
Hospital
Pharmacy

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Vyxeos market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Vyxeos market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Vyxeos companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Vyxeos submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Vyxeos are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Vyxeos market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.